Nchi: Ayalandi
Lugha: Kiingereza
Chanzo: HPRA (Health Products Regulatory Authority)
Rrr alpha-tocoferol
Kora Corporation Limited trading as Kora Healthcare
A11HA03
Rrr alpha-tocoferol
Capsule, soft
tocopherol (vit E)
Not marketed
2023-01-20
1 B. PACKAGE LEAFLET 2 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT METAPEREX 400 IU SOFT CAPSULES RRR-α-tocopherol (Vitamin E) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, or pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Metaperex is and what it is used for 2. What you need to know before you take Metaperex 3. How to take Metaperex 4. Possible side effects 5. How to store Metaperex 6. Contents of the pack and other information 1. WHAT METAPEREX IS AND WHAT IT IS USED FOR Metaperex contains 280 mg RRR-α-tocopherol (equivalent to 400 IU of Vitamin E) Metaperex is indicated in the following conditions for adults: - Vitamin E deficiency in patients diagnosed with ataxia with vitamin E deficiency (AVED). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE METAPEREX _ _ DO NOT TAKE METAPEREX: - If you are allergic to Vitamin E or any of the other ingredients of this medicine (listed in section 6). - Metaperex 400 IU soft capsules contains soya-bean oil. If you are allergic to peanut or soya, do not use this medicinal product. - If you have Vitamin K deficiency (increased risk of bleeding). WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Metaperex. In particular, tell your doctor if: - You lack vitamin K (involved in the blood clotting process). If you take doses of vitamin E above 560 mg per day (equivalent to 800 I.U), you may be more likely to bleed for longer than usual. - You are being treated with blood thiners or the hormone oestrogen. A possible adjustment of the dose of blood thiner medication during a Soma hati kamili
Health Products Regulatory Authority 20 January 2023 CRN00CCC2 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Metaperex 400 IU soft capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains RRR-α-tocopherol 280 mg (equivalent to 400IU of Vitamin E). Excipient with known effect: refined soya-bean oil (146 mg per capsule) For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Capsule, soft Yellow-brown coloured, clear oval shaped soft gelatine capsules with a clear yellow-brown oily liquid. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Metaperex 400 IU soft capsules is indicated in the following conditions for adults: Vitamin E deficiency in patients diagnosed with ataxia with vitamin E deficiency (AVED). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Dosage should be adjusted to the type of disorder and the patient's clinical condition. One international unit (IU) of vitamin E equals the biologic activity of 1 mg of all rac-α-tocopheryl acetate (dl-α-tocopheryl acetate). _ _ For adults diagnosed with AVED the following doses should be administered: 800 IU (560 mg) vitamin E per day (2 capsules) divided into 2 doses. Diagnosis of vitamin E deficiency should be documented and based on: measuring the plasma α-tocopherol level (level < 5μg/mL or <11.6 μmol/L indicates vitamin E deficiency) and/or ratio of plasma α-tocopherol to plasma lipid level (in adults; < 0.8 mg/g total lipid). Plasma vitamin E level should be monitored monthly initially, to ensure levels return to the normal range, thereafter at 6-month intervals and the dose adjusted accordingly if necessary. Method of administration For oral use. Vitamin E is absorbed with lipids, therefore advise patients to take vitamin E during or after a meal to ensure optimal absorption. Health Products Regulatory Authority 20 January 2023 CRN00CCC2 Page 2 of 5 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Metap Soma hati kamili